---
title: "Monozyme India Ltd (522199) — Share Price, Financials & Analysis"
symbol: "522199"
company: "Monozyme India Ltd"
canonical: "https://tapetide.com/stocks/522199"
isin: "INE772D01010"
bse_code: "522199"
sector: "Healthcare"
industry: "Pharmaceuticals & Biotechnology"
generated_at: "2026-09-13T19:02:55.990Z"
---

# Monozyme India Ltd (522199)

Canonical page: https://tapetide.com/stocks/522199

## Company

- **BSE Code:** 522199
- **ISIN:** INE772D01010
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals & Biotechnology
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹5
- **F&O Eligible:** No
- **Website:** monozyme.com

## About

Monozyme India Ltd is engaged in Healthcare/Hospitals business.

## Latest Price

## Key Insights

### Strengths

- Company has reduced debt.

### Weaknesses

- Company has low interest coverage ratio.
- Company has a low return on equity of -24.5% over last 3 years.
- Company has high debtors of 50,127 days.
- Working capital days have increased from 15,794 days to 46,842 days

## Growth Rates

| Metric | 1Y |
| --- | --- |
| net income growth | 51% |
| revenue growth | -99% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Dec 2024 | Dec 2025 |
| --- | --- | --- |
| Sales | 34.63 | 49.28 |
| Expenses | 25.13 | 37.94 |
| Operating Profit | 9.5 | 11.34 |
| OPM % | 27.43 | 23.01 |
| Other Income | 0.08 | 0.03 |
| Interest | 3.41 | 4.57 |
| Depreciation | 5.29 | 4.6 |
| Profit before tax | 0.88 | 2.2 |
| Tax % | -20.45 | 21.36 |
| Net Profit | 1.06 | 1.74 |
| EPS in Rs | 0.43 | 0.71 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 | Mar 2008 |
| --- | --- | --- | --- |
| Sales | 10.55 | 4.96 | 0.03 |
| Expenses | 9.63 | 5.62 | 1.95 |
| Operating Profit | 0.92 | -0.66 | -1.92 |
| OPM % | 8.72 | -13.31 | -6400 |
| Other Income | 0.05 | 0.06 | 2.22 |
| Interest | 0.38 | 0.49 | 0.37 |
| Depreciation | 0.08 | 0.13 | 0.1 |
| Profit before tax | 0.51 | -1.22 | -0.17 |
| Tax % | 35.29 | 7.38 | 0 |
| Net Profit | 0.33 | -1.31 | -0.17 |
| Dividend Payout % | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 | Mar 2008 |
| --- | --- | --- | --- |
| Equity Capital | 3.12 | 3.12 | 3.12 |
| Reserves | -0.23 | -1.54 | -1.71 |
| Borrowings | 5.38 | 4.93 | 2.72 |
| Other Liabilities | 2.96 | 1.49 | 0.72 |
| Total Liabilities | 11.23 | 8 | 4.85 |
| Fixed Assets | 0.71 | 0.59 | 0.4 |
| CWIP | 1.34 | 1.34 | 0 |
| Investments | 0 | 0 | 0 |
| Other Assets | 9.18 | 6.07 | 4.45 |
| Total Assets | 11.23 | 8 | 4.85 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2006 | Mar 2007 | Mar 2008 |
| --- | --- | --- | --- |
| Cash from Operating Activity | -1.35 | — | — |
| Cash from Investing Activity | -1.02 | — | — |
| Cash from Financing Activity | 2.8 | — | — |
| Net Cash Flow | 0.43 | — | — |
| Free Cash Flow | -2.41 | — | — |
| CFO/OP | -127 | — | — |

### Ratios

| Item | Mar 2006 | Mar 2007 | Mar 2008 |
| --- | --- | --- | --- |
| Debtor Days | 189.94 | 330.41 | 50126.67 |
| Inventory Days | 155.01 | 139.97 | 0 |
| Days Payable | 158.32 | 52.76 | — |
| Cash Conversion Cycle | 186.63 | 417.63 | 50126.67 |
| Working Capital Days | 192.36 | 347.34 | 46841.67 |
| ROCE % | — | -9.88 | -5.08 |

## Shareholding Pattern

### annual

| Category | Mar 2024 | Mar 2025 | Jan 2026 |
| --- | --- | --- | --- |
| Promoters | 73% | 73% | 55.12% |
| FIIs | 1.04% | 0.16% | 0% |
| DIIs | 0.44% | 0.5% | 1.39% |
| Public | 25.52% | 26.34% | 43.49% |
| No. of Shareholders | 1717 | 2557 | 2333 |

### Quarterly

| Category | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Jan 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Promoters | 73% | 73% | 73% | 73% | 73% | 55.12% |
| FIIs | 5.25% | 1.04% | 0.94% | 0.16% | 0% | 0% |
| DIIs | 1.59% | 0.44% | 0.13% | 0.5% | 0% | 1.39% |
| Public | 20.16% | 25.52% | 25.93% | 26.34% | 27% | 43.49% |
| No. of Shareholders | 1472 | 1717 | 2707 | 2557 | 2524 | 2333 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 1 / 6 / 12

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 141.65 | Sell |
| EMA (10) | 141.22 | Sell |
| SMA (20) | 149.95 | Sell |
| EMA (20) | 147.15 | Sell |
| SMA (50) | 158.77 | Sell |
| EMA (50) | 156.36 | Sell |
| SMA (100) | 167.88 | Sell |
| EMA (100) | 165.1 | Sell |
| SMA (200) | 179.07 | Sell |
| EMA (200) | 177.72 | Sell |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 34.11 | Neutral |
| MACD (12,26,9) | -6.99 | Sell |
| Stochastic (14,3,3) | 13.58 | Buy |
| ADX (14) | 20.75 | Neutral |
| Williams %R (14) | -74.53 | Neutral |
| ATR (14) | 6.25 | High Volatility |
| ROC (12) | -10.92 | Sell |
| Stoch RSI (14) | 50.82 | Neutral |
| UO (7,14,28) | 40.54 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 4 February 2026 - Clarifies Nov 14, 2025 financial results; no deviation in utilization of Rs.43.26 crore IPO proceeds. | [Reply to Clarification- Financial results 4 February 2026 - Clarifies Nov 14, 2025 financial results; no deviation in utilization of Rs.43.26 crore IPO proceeds.](https://nsearchives.nseindia.com/corporate/CHAVDA_21012026183436_ClarificationLetter.pdf) |
| 28 February 2026 - No deviation in utilization of Rs.43.26 crore IPO proceeds for quarter ended Dec 31, 2025. | [Statement of deviation(s) or variation(s) under Reg. 32 28 February 2026 - No deviation in utilization of Rs.43.26 crore IPO proceeds for quarter ended Dec 31, 2025.](https://nsearchives.nseindia.com/corporate/CHAVDA_28022026144805_SEIntimationRegulation32.pdf) |
| 28 February 2026 - Board approved unaudited standalone results for quarter and nine months ended 31-Dec-2025; limited review attached. | [Outcome of Board Meeting 28 February 2026 - Board approved unaudited standalone results for quarter and nine months ended 31-Dec-2025; limited review attached.](https://nsearchives.nseindia.com/corporate/CHAVDA_28022026144428_SE_IntimationFinancialResults.pdf) |
| 25 February 2026 - Trading window closed from Feb 25, 2026 until 48 hours after unaudited Q3/9M (Dec 31, 2025) results. | [Trading Window 25 February 2026 - Trading window closed from Feb 25, 2026 until 48 hours after unaudited Q3/9M (Dec 31, 2025) results.](https://nsearchives.nseindia.com/corporate/CHAVDA_25022026180735_TradingWindowClosure31122025.pdf) |
| 22 January 2026 - Board allotted 8,000,000 shares at Rs114 each on Jan 22, 2026; proceeds Rs91.20 crore. | [Outcome of Board Meeting 22 January 2026 - Board allotted 8,000,000 shares at Rs114 each on Jan 22, 2026; proceeds Rs91.20 crore.](https://nsearchives.nseindia.com/corporate/CHAVDA_22012026181826_BM_Outcomeallotmentfinalequity80lakhs.pdf) |
| 22 January 2026 - Allotment of 80,00,000 shares at Rs114 each; proceeds Rs91.20 crore; issued Jan 22, 2026. | [Outcome of Board Meeting 22 January 2026 - Allotment of 80,00,000 shares at Rs114 each; proceeds Rs91.20 crore; issued Jan 22, 2026.](https://nsearchives.nseindia.com/corporate/CHAVDA_22012026180627_BM_Outcomeallotmentfinalequity80lakhs.pdf) |
| 22 January 2026 - Allotment of 8,000,000 shares at Rs.114 on Jan 22, 2026; proceeds Rs.91.20 crore. | [General Updates 22 January 2026 - Allotment of 8,000,000 shares at Rs.114 on Jan 22, 2026; proceeds Rs.91.20 crore.](https://nsearchives.nseindia.com/corporate/CHAVDA_22012026182101_BM_Outcomeallotmentfinalequity80lakhs.pdf) |
| 14 January 2026 - Certificate under SEBI Regulation 74(5) submitted for quarter ended 31-Dec-2025 confirming dematerialisation details. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 14 January 2026 - Certificate under SEBI Regulation 74(5) submitted for quarter ended 31-Dec-2025 confirming dematerialisation details.](https://nsearchives.nseindia.com/corporate/CHAVDA_14012026160535_SEIntimationReg74_5_.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| May 2025 | [Concall - May 2025](https://nsearchives.nseindia.com/corporate/CHAVDA_30052025150908_ChavdaInvestorPresentation.pdf) |
| Jun 2025 | [Concall - Jun 2025](https://nsearchives.nseindia.com/corporate/CHAVDA_02062025214300_ChavdaTranscriptEarningCallFY25.pdf) |
| Jun 2024 | [Concall - Jun 2024](https://nsearchives.nseindia.com/corporate/CHAVDA_14062024110214_Reg30_InvestorPresentation.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_28923_CHAVDA_2024_2025_A_12916182_08092025175753.pdf) |
| from nse | [Financial Year 2024 from nse](https://archives.nseindia.com/annual_reports/SME_AR_25607_CHAVDA_2023_2024_03092024193357.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:02:55.990Z.